Hijioka Susumu, Nagashio Yoshikuni, Maruki Yuta, Kawasaki Yuki, Takeshita Kotaro, Morizane Chigusa, Okusaka Takuji
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
Diagnostics (Basel). 2023 Mar 28;13(7):1275. doi: 10.3390/diagnostics13071275.
In recent years, cancer genomic medicine centered on comprehensive genome profile (CGP) analysis has become widely used in the field of pancreatic cancer. Endoscopic ultrasound-guided tissue acquisition (EUS-TA) has played an important role in pancreatic cancer, and recently, more EUS-TA tissue samples are considered for CGP analysis. Differences exist between the Oncoguide NCC Oncopanel System and Foundation One CDx Cancer Genome Profile, which are CGP tests approved by insurance programs in Japan, including the analysis criteria, optimal needle selection for meeting these criteria, and puncture target. It is important to understand not only the specimen collection factors, but also the specimen processing factors that can increase the success rate of CGP testing. Furthermore, cancer genome medicine is expected to enter an era of increasing turbulence in the future, and endoscopists need to respond flexibly to these changes. Herein, we review the current status of cancer genome medicine in pancreatic and biliary tract cancers and cancer gene panel testing using EUS-TA.
近年来，以综合基因组图谱（CGP）分析为核心的癌症基因组医学在胰腺癌领域得到了广泛应用。内镜超声引导下组织获取（EUS-TA）在胰腺癌中发挥了重要作用，最近，越来越多的EUS-TA组织样本被用于CGP分析。Oncoguide NCC Oncopanel系统和Foundation One CDx癌症基因组图谱之间存在差异，这两种都是日本保险计划批准的CGP检测，包括分析标准、满足这些标准的最佳穿刺针选择以及穿刺靶点。不仅要了解标本采集因素，还要了解能够提高CGP检测成功率的标本处理因素，这一点很重要。此外，癌症基因组医学预计在未来将进入一个更加动荡的时代，内镜医师需要灵活应对这些变化。在此，我们综述了胰腺癌和胆管癌中癌症基因组医学的现状以及使用EUS-TA进行癌症基因检测的情况。
